PrSandoz[®] AFAtinib

A generic equivalent of ^{Pr}Giotrif®

SANDOZ





 Appearance of 20 mg, 30 mg and 40 mg tablet similar to the reference product.

^{Pr} Sandoz® AFAtinib	PrGiotrif®	STRENGTH	DIN	UPC	FORMAT
AF 20		20 mg	02512777	0 57513 22194 1	Blisters of 30 tablets
AF 30	130 T 30	30 mg	02512785	0 57513 22195 8	
AF 40	,îi, T 40	40 mg	02512793	0 57513 22196 5	

*Sandoz® AFAtinib (afatinib dimaleate tablets) is indicated as: • monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patient with metastatic (including cytologically proven pleural effusion) adenocarcinoma of the lung with activating EGFR mutation(s); monutory, monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology progressing after platinum-based chemotherapy.

For more information, please contact your local Sandoz Regional Manager. Please consult Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4. ^{pr}Giotrif[®] is registered trademark of Boehringer Ingelheim International GmbH.



Sandoz Canada Inc. 110, rue de Lauzon, Boucherville (Québec) J4B 1E6 sandoz.ca

SANDOZ




THIS PRODUCT IS SUPPORTED BY



Support you can trust

Sandoz partners with all pharmacies in Canada to make our medication available in the pharmacy chosen by your patients.

SANDOZ PROGRAM OFFERS SERVICES BASED ON PATIENTS' NEEDS.



© 2024 Sandoz Canada Inc.



Sandoz Canada Inc. 110 de Lauzon, Boucherville (Quebec) J4B 1E6 sandoz.ca

SANDOZ